Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemisch - immunosuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - longaandoening, chronisch obstructief - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Europese Unie - Nederlands - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastische middelen - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - terbutalinesulfaat 0,25 mg/dosis - inhalatiepoeder - geen hulpstoffen, - terbutaline

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - terbutalinesulfaat 500 µg/dosis samenstelling overeenkomend met ; terbutaline 411 µg/dosis - inhalatiepoeder - lactose 1-water, geen hulpstoffen, - terbutaline

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - omeprazol natrium, 1-water samenstelling overeenkomend met ; ; omeprazol - poeder voor oplossing voor infusie - dinatriumedetaat 2-water ; natriumhydroxide (e 524) ; stikstof (head space) (e 941), - omeprazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - omeprazol natrium, 1-water samenstelling overeenkomend met ; ; omeprazol - poeder en oplosmiddel voor oplossing voor injectie - citroenzuur 1-water (e 330) ; natriumhydroxide (e 524) ; polyethyleenglycol (e 1521) ; stikstof (head space) (e 941) ; water, gezuiverd, - omeprazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

astrazeneca b.v prinses beatrixlaan 582 2595 bm den haag - formoterolfumaraat 2-water 12 µg/dosis samenstelling overeenkomend met ; formoterol 9,8 µg/dosis - inhalatiepoeder - lactose 1-water, - formoterol